Drug interactions during therapy with three major groups of antimicrobial agents.
about
Drug interactions--principles, examples and clinical consequencesElderly patients and inflammatory bowel diseaseAspergillus fumigatus in the cystic fibrosis lung: pros and cons of azole therapyRisks associated with the therapeutic use of fluoroquinolones.Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents.Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective.Cethromycin: a promising new ketolide antibiotic for respiratory infections.Pharmacogenomics of the triazole antifungal agent voriconazole.Elderly patients with community-acquired pneumonia: optimal treatment strategies.Inflammatory bowel disease of the elderly: frequently asked questions (FAQs).Management of the elderly patients with inflammatory bowel disease: practical considerations.Systematic review with meta-analysis: inflammatory bowel disease in the elderly.Safety issues and drug-drug interactions with commonly used quinolones.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Inhibitory Effects of Multiple-Dose Treatment with Baicalein on the Pharmacokinetics of Ciprofloxacin in Rats.Concomitant prescription of oral fluoroquinolones with an antacid preparation.Inflammatory bowel disease of the elderly: a wake-up call.Pharmacokinetic interaction between telithromycin and metformin in diabetes mellitus rats.The effects of a short course of antibiotics on alvimopan and metabolite pharmacokinetics.Antileishmanial Efficacy and Pharmacokinetics of DB766-azole Combinations.A record of 1320 suspect, deferasirox-related, patient deaths reported in 2009: insufficient toxicity testing, low efficacy and lack of transparency may endanger the lives of iron loaded patients.Interactions of hydroxycarbamide (hydroxyurea) with iron and copper: implications on toxicity and therapeutic strategies.
P2860
Q24599421-0D0699C6-26FD-43F2-9252-BA19E628C966Q26768270-25D0AC86-69F6-47DA-B0F8-2A53DC8F38B1Q28074671-A9B964FA-A463-4587-9DEF-33115B5AB959Q34343391-BE4D2BEC-D31D-4AA2-8862-757A18F4A9D3Q37048679-12BD1C5D-19CC-4193-A42C-0AA0E4790049Q37157893-308AD7A2-101E-47FD-94F5-7425EBD247D0Q37638755-70D63C8C-EF7D-43C3-B488-437D046F7CF2Q37697782-B1DBB61B-2C22-410A-9A17-AE40D7231EC0Q37892536-6B673B75-3D1C-43B3-9FA1-4372250FE826Q37896600-B2087944-1434-403F-9DA8-0E6C4C96461CQ37921606-F023DB7B-B884-425A-9F5E-A0311576A67BQ38122069-C271DF1C-D7C3-4967-93CC-E23659C8F5D4Q38176953-0495C25E-9CBF-4382-93D5-C334874D84DCQ38271318-9E315F86-0FDA-4F3A-A7BE-8DD1295D942FQ38284468-9317A023-7F75-449A-BF98-D052E1BAC247Q40526599-BC39B0FC-0298-4544-BFEA-621AA9CA28E2Q41347294-77627090-96BC-4EF3-BDC4-6490E7805B57Q42019607-26ADEAC0-56B6-4DF7-A6AD-6217D08FAB4AQ43205619-1F3A0D22-9397-493F-9B2E-CD3B9B4E29EDQ43268377-75F784F4-8689-4821-9B3A-70AA215ACCE5Q46430242-2BC821DC-0220-4A65-BF53-F77561B36AB8Q48665941-2ABB1401-E442-4461-8BA7-F41E3EDE68CBQ53153263-92D9308C-63B0-4C13-8354-60E1C588D7D7
P2860
Drug interactions during therapy with three major groups of antimicrobial agents.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Drug interactions during therapy with three major groups of antimicrobial agents.
@ast
Drug interactions during therapy with three major groups of antimicrobial agents.
@en
type
label
Drug interactions during therapy with three major groups of antimicrobial agents.
@ast
Drug interactions during therapy with three major groups of antimicrobial agents.
@en
prefLabel
Drug interactions during therapy with three major groups of antimicrobial agents.
@ast
Drug interactions during therapy with three major groups of antimicrobial agents.
@en
P2860
P356
P1476
Drug interactions during therapy with three major groups of antimicrobial agents.
@en
P2093
Kasra Shakeri-Nejad
Ralf Stahlmann
P2860
P304
P356
10.1517/14656566.7.6.639
P407
P577
2006-04-01T00:00:00Z